Stratera Biopharma (STAB) is a clinical-stage biopharmaceutical company developing innovative immunotherapies targeting a wide host of health issues people may face today. Specifically, these therapeutics harness (and trick) one’s own immune system into coming to the body’s defense against autoimmune diseases (diseases where the body attacks its own organ systems), inflammation, infections, and even cancer. Their current clinical trials and innovation regarding novel therapeutics for Crohn’s Disease, Pancreatic Cancer, COVID and more are setting the stage for incredible promise of a return to their previous $4-$7 NASDAQ stock pps levels.
The biopharmaceutical market is undergoing explosive growth, given growing acceptance of biologics, monoclonal antibodies, and other bioengineered therapeutics. According to Acumen Research, “the US is the world’s largest funder of biomedical R&D investment over the past two decades,” and “the global biopharmaceutical market is expected to grow at a CAGR of around 7.3% from 2020 to 2027 and expected to reach the market value of around US$ 535 Bn by 2027”.
During the worldwide SARS-CoV-2 pandemic, it was the biopharmaceutical industry that was able to rapidly deploy their state-of-the-art R&D engine toward the development of monoclonal antibodies and other agents to help mitigate and combat the infectious disease and resulting cascade of symptoms in afflicted individuals. Global governments made way for quick and timely approval processes, and in general, are highly invested in the relationship between overall public health and the economy, which the biopharmaceutical industry mediates in terms of being the catalyst that changed/changes the direction of the pandemic, public health infectious disease and other ills that affect the populace.
So, as one can see, there is VAST potential for successful biopharma companies in this sector. As mentioned at the outset, Stratera is not only invested in research efforts of COVID, but they’re investigating other common infectious diseases, cancer, and autoimmune diseases. Everyone knows someone, or multiple people, who may be dealing with at least one of these issues. Successful clinical trials and bringing biopharmaceutical agents to the FDA for approval would contribute significantly to the improvement of millions of lives.
STAB recently obtained IRB approval to proceed with the final clinical trial for their pediatric Crohn’s Disease treatment research and have multiple projects currently in the pipeline, all of which, according to the company’s tagline, have an aim toward “changing the way people think about immunotherapy,” not to mention of course, the goal of improving and saving lives. This company’s stock pps was over $4 a few months ago and was well over $6 (closer to $7) a year ago. A recent acquisition was a large focus of the company this past year, and according to CEO Michael K. Handley, they expect to see the fruits of their labor and efforts in 2022. The potential is simply huge on this. We are at bottom now, and they’re not going to simply relinquish their NASDAQ status here. Expect a big reversal soon, and onward as more and more good news comes in from their clinical trials and biopharmaceuticals development. Grab some while you can!